🧵Si quieres tener exposición al sector lujo una buena idea puede ser Watches of Switzerland $WOSG ⌚ Cotiza a unas 12,5 EV/FCF, deuda neta/EBITDA de 0,1 y capitaliza unos 2B.
🏃♂️ I've gamified my own run so I can race my own ghost with the Meta Ray-Ban Display.
I built a web app for the glasses, loaded a previous GPX from Strava, and dropped game mechanics on top.
Pick up coins when you keep pace, sprint zones reward extra points if you push, and a mini leaderboard on the lens shows how you're tracking against your past self in real time.
Best part: it actually works. Seeing your ghost 20 m ahead is a way stronger nudge than any number on a watch. 😅
Thank you. The important part is zeroing out taxes on the bottom half. Best way to put money in someone’s pocket is to not take it out in the first place. Bottom half is only 3% of total tax revenue. But it’s very meaningful to that person. Zero it out.
@CapitalFaktory Era la final anticipada que todos merecíamos. Lo bueno, de esta forma hay 2 partidos. Vaya ritmo e intensidad de partido. Hoy me he levantado con las piernas cargadas 🙊
🎉 ID Research cumple 1 año.
Para celebrarlo he preparado un sorteo doble con 7 ganadores en total:
Te cuento qué hay que hacer y qué se llevan los ganadores
🎁 Sorteo abierto para todos (2 ganadores):
✅ 1 año de suscripción a ID Research
Para participar:
- Sígueme por X y S🟠tack
- RT a este tweet
🔐Sorteo solo para suscriptores de pago (5 ganadores):
🤖 2x Claude Pro (3 meses)
📕 "Aquí no hay reglas" (Netflix)
📗 "The Upstarts" (Uber y Airbnb)
📘 Biografía de Elon Musk (Walter Isaacson)
Si ya eres suscriptor de pago, no tienes que hacer nada. Ya participas automáticamente.
¿No lo eres todavía? Tienes una semana para suscribirte.
Ambos sorteos se resuelven el domingo 3 de mayo que coincide con el primer aniversario de ID Research.
¡Suerte a todos! 🍀
@ID_Research_ Primero hago las series de aproximación en el primer ejercicio. Luego con el peso marcado (todas las series mismo peso) voy a un rango de reps (x ejemplo 8-12) con objetivo de estar en RIR 0-2. Entre series descanso 3min en musculos grandes y 2 en pequeños. He notado mucha mejora
Yo pienso que es lo idóneo para todo el mundo
Especializarte en 20-30 empresas. Llevar unas 10 de ellas, imagínate un (30% del patrimonio) y el resto a lo que dices, o fondos de gestión activa que te dejen tranquilo
Para alguien que no se dedique 100% a esto, pero quiera mantener esa tensión intelectual, es lo mejor yo creo
With public software valuations on a large drawdown due to AI concerns, I’ve gone back to basics to reconfirm conviction. Although $VHI.TO did not report a blow out quarter, it was largely on the mark and continues to be a good operator putting up consistently improving results. I continue to have a high level of conviction in the name.
Long Term Thesis
Quality Management and Board
· Founder Led – Skin in the Game by Management and Board – CEO has deep healthcare IT experience.
· Track Record of Past Success – both CEO and Chairman have founded and ran organizations resulting in an exit and a positive outcome for shareholders.
High Business Quality
· High revenue predictability and profitability - recurring revenue model with peer leading organic growth, sticky solution via high switching costs resulting in low customer churn risk, asset light.
· High quality end market - Positive demographic trends (i.e. aging population driving healthcare demand, public health agencies need tech to meet demand) and effectively recession proof product.
· AI disruption risk exists at a theoretical level but I feel good about the moat plus company is not standing still and is embracing AI tools in its development and operations.
Strong Ability to Reinvest Cash Flows
· Runway – robust M&A pipeline and a track record of deploying capital
· Playbook – proven playbook to acquire, integrate and drive synergies optimizing R&D and cross selling highly related products driving organic growth
· Balance Sheet – rock solid with no debt and cash of $119M+ with total liquidity of $184M+
· Dilution – it’s a concern but generally ok with me if they keep executing their M&A strategy accretively above cost of capital
Things I’m monitoring:
· Rule of 40 Guidance – Monitoring progression to rule of 40 which management suggest they’ll hit in 2026 with Organic growth of 10%-12% with the balance coming from Adjusted EBITDA Margin. Plan to meet it with a mix of further cost reductions via optimizing R&D and ongoing ARR growth without an offsetting scaling of costs.
· Recurring Revenue – For the first time in recent history quarterly recurring revenue was sequentially flat at $23.6M despite a higher ARR reported in the quarter. Management has provided a plausible explanation but this is important to verify so we should see a sequential increase here next quarter. I’m not alarmed as I have high confidence in management and past explanations given have always been accurate.
· Gross Margin – Looking for this to improve back up to 80%+
· Working Capital Movements – many of the annual subscription billings are tied to government budgeting cycles resulting in quarterly swings from a working capital perspective with Q2 and Q3 seasonally being strong collection periods and Q4 being the low point. Now this Q4 was a bit lower than expected but nevertheless I expect working capital to fluctuate back in Q2/Q3 as it has done in past years.
· Receivables – Unbilled Revenue and AR outstanding > 90 days has increased to elevated levels with the acquisition of Induction and Novari. This was addressed by management on the call that practices have been changed and improvements have been made so I expect that to flow through the financial results over the next few quarters.
Imagina que no hay cotizaciones, todas tus empresas son privadas.
No puedes ver los precios. Qué vigilas? Resultados financieros? Decisiones estratégicas? Reinversión?
Pues deja de ver precios y vigila eso siempre. Los precios de un año a otro no te dan ni te quitan razón.